<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>orforglipron &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/orforglipron/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Wed, 07 Oct 2026 23:37:29 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.3</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>orforglipron &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Higher Dose of Oral Weight-Loss Pill Orforglipron Delivers Greater Results, Meta-Analysis Finds</title>
		<link>https://bioengineer.org/higher-dose-of-oral-weight-loss-pill-orforglipron-delivers-greater-results-meta-analysis-finds/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Wed, 07 Oct 2026 23:37:29 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[cardiometabolic health]]></category>
		<category><![CDATA[dose comparison]]></category>
		<category><![CDATA[drug safety]]></category>
		<category><![CDATA[GLP-1 receptor agonist]]></category>
		<category><![CDATA[HbA1c]]></category>
		<category><![CDATA[Meta-analysis]]></category>
		<category><![CDATA[obesity]]></category>
		<category><![CDATA[oral medication]]></category>
		<category><![CDATA[orforglipron]]></category>
		<category><![CDATA[randomized controlled trials]]></category>
		<category><![CDATA[Type 2 diabetes]]></category>
		<category><![CDATA[Weight Loss]]></category>
		<guid isPermaLink="false">https://bioengineer.org/?p=406509</guid>

					<description><![CDATA[A new meta-analysis of six randomized controlled trials finds that the 36 mg maintenance dose of the oral GLP-1 agonist orforglipron produces significantly greater weight and metabolic improvements than 12 mg in adults with obesity, with comparable safety outcomes.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">406509</post-id>	</item>
	</channel>
</rss>
